Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0F9QY
|
|||
| Former ID |
DIB018579
|
|||
| Drug Name |
3,3'-difluorobenzaldazine
|
|||
| Synonyms |
3,3'-Difluorobenzaldazine; DFB; 15332-10-2; CHEMBL371811; 1,2-Bis(3-Fluorobenzylidene)Hydrazine; AC1O7H0M; SCHEMBL12017614; SCHEMBL12497017; bis(3-fluorobenzylidene)hydrazine; CHEBI:92414; MolPort-003-940-930; HMS3262J07; Tox21_500843; DFB, > MFCD03653615; BDBM50156074; ZINC13719901; AKOS024456711; VZ25360; CCG-222147; NCGC00261528-01; NCGC00025238-05; NCGC00025238-02; NCGC00025238-03; NCGC00025238-04; KB-76455; SR-01000597595; C-14798; J-009001; SR-01000597595-1; 3,3 inverted exclamation marka-Difluorobenzaldazine
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL
|
||
| Formula |
C14H10F2N2
|
|||
| Canonical SMILES |
C1=CC(=CC(=C1)F)C=NN=CC2=CC(=CC=C2)F
|
|||
| InChI |
1S/C14H10F2N2/c15-13-5-1-3-11(7-13)9-17-18-10-12-4-2-6-14(16)8-12/h1-10H/b17-9+,18-10+
|
|||
| InChIKey |
YYMCVDNIIFNDJK-BEQMOXJMSA-N
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
24640122, 43224630, 50104919, 50104920, 75885289, 85787621, 90341252, 91703710, 96052388, 103458889, 104043354, 114638185, 121361631, 124887046, 135698435, 144240231, 162248416, 163781288, 164821009, 175612575, 179335167, 184557883, 189353164, 206247677, 237140121, 237559857, 241182585, 241375544, 252365683
|
|||
| ChEBI ID |
CHEBI:92414
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Metabotropic glutamate receptor 5 (mGluR5) | Target Info | Modulator (allosteric modulator) | [2] |
| KEGG Pathway | Calcium signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Gap junction | ||||
| Long-term potentiation | ||||
| Retrograde endocannabinoid signaling | ||||
| Glutamatergic synapse | ||||
| Huntington's disease | ||||
| Panther Pathway | Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||
| Metabotropic glutamate receptor group III pathway | ||||
| Metabotropic glutamate receptor group I pathway | ||||
| Endogenous cannabinoid signaling | ||||
| Reactome | G alpha (q) signalling events | |||
| Class C/3 (Metabotropic glutamate/pheromone receptors) | ||||
| WikiPathways | Hypothetical Network for Drug Addiction | |||
| GPCRs, Class C Metabotropic glutamate, pheromone | ||||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1424). | |||
| REF 2 | A family of highly selective allosteric modulators of the metabotropic glutamate receptor subtype 5. Mol Pharmacol. 2003 Sep;64(3):731-40. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.